TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases.
The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts. The company trades on NCM exchange. The company headquarter is located in Boston ,United States.
| Ticker | RNAZ |
| Long Name | TransCode Therapeutics, Inc. Common Stock |
| Short Name | TransCode Therapeutics, Inc. |